.svg){kind=small}
Aug-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
Dosecann’s August 2026 mix is concentrated in Capsules at 47.45% share with year-over-year down 63.04% and month-over-month down 12.37%, while Vapor Pens hold 27.20% share with year-over-year down 30.74% and month-over-month down 30.67%. Oil contributes 20.40% share with year-over-year down 72.07% and month-over-month down 17.63%, and Topical is 4.95% share with year-over-year down 91.82% and month-over-month up 35.99%. The weighted impact is a brand-level year-over-year decline of 66.97% alongside a modest 1.59% average price rise, implying a contraction concentrated in Capsules and Oil even as Topical volatility and Vapor Pens retrench; the net pattern points to overreliance on Capsules amid falling category momentum.
The shift indicates positioning anchored in Capsules where the brand sits at rank 14 in Ontario, with a 12.37% month-over-month drop and a 63.04% year-over-year contraction signaling weakening pull against faster-moving inhalable formats. Vapor Pens’ 30.67% month-over-month decline versus Topical’s 35.99% month-over-month rebound suggests portfolio whiplash that dilutes channel consistency, while Oil’s 72.07% year-over-year fall paired with a 17.63% month-over-month slide raises substitution risk toward lower-priced inhalables given the brand’s 1.59% average price increase and a Capsules average price of $35.57. The implied path is to defend Capsules share while reallocating toward steadier, less volatile formats to reduce exposure to double-digit month-over-month declines.
Competitive Landscape
Dosecann ranks #14 in ON Capsules in August 2026, sliding 3 positions year over year from #11, while holding flat versus May–July at #14; that contrasts with Aspire holding #1 with a 0-position YoY change and Glacial Gold climbing from #4 to #2 alongside a 43.3% YoY sales increase. Dosecann’s current #14 sits seven spots below its #7 peak in September 2024, whereas Emprise Canada moved up from #5 to #3 with a 61.4% YoY gain and Redecan fell from #2 to #5 with a 41.1% YoY decline; against this mix of ascenders and decliners, Dosecann’s 3-rank YoY drop and multi-month stasis at #14 imply a mid-tier position eroding relative to faster-moving rivals.
Notable Products
Forbidden Fruit Distillate Cartridge (1g) posted a -51.9% month-over-month decline and slid to rank 5, while CBD Oil (30ml) fell -14.1% at rank 2, indicating Vapor Pens weakness outpaced Oil softness. CBD 50 Capsules 30-Pack (1500mg CBD) also dropped -17.7% yet remained rank 1, and Capsules accounted for three of the top ten placements, signaling that Dosecann’s core volume still concentrates in ingestibles despite cartridge volatility.
Amid broad declines, CBD 50 Softgels 30-Pack (1500mg CBD ) rose +11.9% at rank 4 and the CBD/THC Daily Relief Cream (1200mg CBD, 40mg THC, 60ml) increased +36.0% at rank 8, contrasting with the CBD Capsules 30-Pack (750mg CBD) collapse of -79.7% at rank 9 and the CBD:THC 25:1 Oil (30ml) drop of -34.2% at rank 7. With top-line anchored by approximately $17,020 from CBD 50 Capsules 30-Pack (1500mg CBD) and three Capsules SKUs in the top ten, the mix points toward Dosecann prioritizing high-potency capsule retention while deprioritizing breadth in lower-potency and legacy oil formats.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
